Zileutonum [INN-Latin]
Brand names,
Zileutonum [INN-Latin]
Analogs
Zileutonum [INN-Latin]
Brand Names Mixture
Zileutonum [INN-Latin]
Chemical_Formula
C11H12N2O2S
Zileutonum [INN-Latin]
RX_link
http://www.rxlist.com/cgi/generic/zileuton.htm
Zileutonum [INN-Latin]
fda sheet
Zileutonum [INN-Latin]
msds (material safety sheet)
Zileutonum [INN-Latin]
Synthesis Reference
No information avaliable
Zileutonum [INN-Latin]
Molecular Weight
236.291 g/mol
Zileutonum [INN-Latin]
Melting Point
144.2-145.2 oC
Zileutonum [INN-Latin]
H2O Solubility
Practically insoluble (0.5 mg/ml)
Zileutonum [INN-Latin]
State
Solid
Zileutonum [INN-Latin]
LogP
1.437
Zileutonum [INN-Latin]
Dosage Forms
Tablet (600mg)
Zileutonum [INN-Latin]
Indication
For the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
Zileutonum [INN-Latin]
Pharmacology
Zileuton is an asthma drug. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma.
Zileutonum [INN-Latin]
Absorption
Rapidly and almost completely absorbed. The absolute bioavailability is unknown.
Zileutonum [INN-Latin]
side effects and Toxicity
The oral minimum lethal doses in mice and rats were 500-4000 and 300-1000 mg/kg in various preparations, respectively (providing greater than 3 and 9 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose, respectively).
Zileutonum [INN-Latin]
Patient Information
Patients should be told that:
- ZYFLO is indicated for the chronic treatment of asthma and should be taken regularly as prescribed, even during
symptom-free periods.
- ZYFLO is not a bronchodilator and should not be used to treat acute episodes of asthma.
- When taking ZYFLO, they should not decrease the dose or stop taking any other antiasthma medications unless
instructed by a physician.
- While using ZYFLO, medical attention should be sought if short-acting bronchodilators are needed more often
than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed
for a 24-hour period are needed.
- The most serious side effect of ZYFLO is elevation of liver enzyme tests and that, while taking ZYFLO, they
must return for liver enzyme test monitoring on a regular basis. If they experience signs and/or symptoms of liver
dysfunction (e.g., right upper quadrant pain, nausea, fatigue, lethargy, pruritus, jaundice, or "flu-like"
symptoms), they should contact their physician immediately.
- ZYFLO can interact with other drugs and that, while taking ZYFLO, they should consult their doctor before
starting or stopping any prescription or non-prescription medicines.
A patient leaflet is included with the tablets.
Zileutonum [INN-Latin]
Organisms Affected
Humans and other mammals